Method of Treating a Malignancy in a Subject and a Pharmaceutical Composition for Use in Same

• US 20150037287A1
• Filed: 03/31/2014
• Published: 02/05/2015
• Est. Priority Date: 11/25/1999
• Status: Abandoned Application

• Current Assignee: Viralytics Limited (Merck & Co., Inc.)
• Original Assignee: Viralytics Limited (Merck & Co., Inc.)
• Inventors: Shafren, Darren R.
• Application Number:
  US14/231,528
• Publication Number:
  US 20150037287A1
• Time in Patent Office: Days
• US Class Current: 424/93.6
• CPC Class Codes: A61K 35/768 Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: C12N 2770/32332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2770/32333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
• CPC Class Codes: C12N 2770/32371 Demonstrated in vivo effect
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: C12Q 1/025 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics antimicrobial activity C12Q1/18
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity

Abstract

There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.

Claims

1-129. -129. (canceled)

130. A method of treating non-small cell lung cancer (NSCLC) in a mammal, comprising administering to the mammal an effective amount of a human Enterovirus-C (HEV-C), wherein the virus is Coxsackievirus A21 (CVA21), that binds to intercellular adhesion molecule-1 (ICAM-1) for infectivity of the NSCLC cells and is thereby capable infecting the cells whereby death of the cells is caused, wherein CVA21 is administered intravenously, intratumorally, intraperitoneally or intramuscularly.

133. The method of claim wherein expression of ICAM-1 is upregulated on the abnormal cells relative to cells of surrounding tissue in which the abnormal cells are found.